Namrata S. Patil
Genentech · 77 works · 3,187 citations · h-index 23
Top works
- Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
- Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
- Accessory molecules for MHC class II peptide loading
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
- Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
- A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
- Molecular determinants of response to PD-L1 blockade across tumor types
- Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
- Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
- SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
- Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
- Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes
- Rheumatoid Arthritis (RA)-Associated HLA-DR Alleles Form Less Stable Complexes with Class II-Associated Invariant Chain Peptide Than Non-RA-Associated HLA-DR Alleles
- Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
- Clonal Hematopoiesis in Late-Stage Non–Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing
- ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
- Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
- Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
- Characterization of HLA DR3/DQ2 transgenic mice: a potential humanized animal model for autoimmune disease studies